Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gynaecologic effects of tamoxifen.

Literature DB >> 8535666

Gynaecologic effects of tamoxifen.

Abstract

Tamoxifen, an estrogen antagonist, is widely used as adjuvant therapy in patients with breast cancer. Its efficacy in increasing survival and reducing recurrence rates has been demonstrated in several European and American studies. However, its effects appear to be tissue specific. Tamoxifen exerts an estrogen effect (agonist) on the endometrium, myometrium and vagina. An increase in uterine cancer has been confirmed in several placebo-controlled clinical trials. Due to the widespread use of this drug, it is timely to review the gynecologic effects of tamoxifen.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1995 PMID： 8535666 DOI： 10.1007/bf01676708

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

75 in total

1. Endometriosis developing during tamoxifen therapy.

Authors: M R Ford; M J Turner; C Wood; W P Soutter
Journal: Am J Obstet Gynecol Date: 1988-05 Impact factor: 8.661

2. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer.

Authors: M Andersson; H H Storm; H T Mouridsen
Journal: J Natl Cancer Inst Date: 1991-07-17 Impact factor: 13.506

3. Endometrial hyperplasia in an oophorectomized woman receiving tamoxifen therapy. Case report.

Authors: S S Cross; S M Ismail
Journal: Br J Obstet Gynaecol Date: 1990-02

4. Tamoxifen as risk factor for carcinoma of corpus uteri.

Authors: L Hardell
Journal: Lancet Date: 1988-09-03 Impact factor: 79.321

5. Cystic ovarian necrosis complicating tamoxifen therapy for breast cancer in a premenopausal woman. A case report.

Authors: C J Jolles; D Smotkin; K L Ford; K P Jones
Journal: J Reprod Med Date: 1990-03 Impact factor: 0.142

6. Tamoxifen and partial oestrogen agonism in postmenopausal women.

Authors: A Miodrag; P Ekelund; R Burton; C M Castleden
Journal: Age Ageing Date: 1991-01 Impact factor: 10.668

7. Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen.

Authors: I Cohen; D J Rosen; R Tepper; M Cordoba; Y Shapira; M M Altaras; D Yigael; Y Beyth
Journal: J Ultrasound Med Date: 1993-05 Impact factor: 2.153

8. Oncogenic potential of tamoxifen on endometria of postmenopausal women with breast cancer--preliminary report.

Authors: D Gal; S Kopel; M Bashevkin; J Lebowicz; R Lev; M L Tancer
Journal: Gynecol Oncol Date: 1991-08 Impact factor: 5.482

9. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.

Authors: I Cohen; R Tepper; D J Rosen; J Shapira; M Cordoba; Y Dror; M Altaras; Y Beyth
Journal: Gynecol Oncol Date: 1994-10 Impact factor: 5.482

10. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.

Authors: A Manni; O H Pearson
Journal: Cancer Treat Rep Date: 1980 Jun-Jul

1 in total

1. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms.

Authors: J J Watters; D M Dorsa
Journal: J Neurosci Date: 1998-09-01 Impact factor: 6.167

1 in total